History
ICON was founded in Dublin, Ireland, by John Climax and Ronan Lambe in 1990. Since January 2010, Climax has held a position on the board of directors. Lambe retired from the board of directors in 2018. Between 1991 and 1996, ICON opened offices in the United Kingdom, United States, and Japan. A year later, ICON shares started to be traded on Nasdaq. In 2018, ICON won the ''PharmaTimes'' Clinical Researcher of the Year. ICON received 2019 Clinical Research Organization leadership awards in five categories, determined by ''Life Science Leader'' magazine and Industry Standard Research (ISR). In March 2017, Steve Cutler was appointed Chief Executive Officer of ICON. He had previously been with Quintiles South Africa,2021 Acquisition of PRA Health Sciences
In 2013 the company was acquired byAcquisitions
* 2000: ICON acquired UK-based regulatory consultancy, YRCR Ltd.; Central Laboratory in New York; and bioanalytical consultancy, Pacific Research * 2002: ICON acquired clinical research provider, BPA. * 2003: ICON acquired Medeval, a UK-based Phase I facility, and US consulting firm, Globomax * 2004: ICON acquired medical imaging specialist, Beacon Bioscience Inc. * 2006: ICON acquired outcomes research and health economics specialist, Ovation Research Group * 2007: ICON acquired European staffing group, DOCS International * 2008: ICON acquired US phase I provider, Healthcare Discoveries and US bioanalytical lab, Prevalere Life Sciences * 2009: ICON acquired Veeda Laboratories, a UK biomarker lab * 2010: ICON acquired Timaq Medical Imaging Inc. * 2011: ICON acquired Oxford Outcomes, an international health outcomes consultancy and Firecrest Clinical, a technology provider specialising in site performance and study management * 2012: ICON acquired PriceSpective, a global value strategy consultancy and Chinese CRO, BeijingWits * 2013: ICON acquired staffing and FSP providers, ClinForce and Assent and Akos, an EU provider of pharmacovigilance and drug safety services * 2014: ICON acquired Aptiv Solutions, a market leader in adaptive trial design and execution * 2015: ICON acquired MediMedia Pharma Solutions to enhance market access and scientific communications capabilities, and PMG Research Inc., an integrated network of clinical research sites in the US * 2016: ICON acquired Clinical Research Management Inc., to extend its presence in the government-sponsored research market * 2017: ICON acquired MAPI Group, thereby becoming the world’s second-largest provider of late-phase services * 2019: ICON acquired Symphony Clinical Research, a leading provider of at-home patient services and site-support services; MediNova, an integrated network of clinical research sites across EMEA; and MolecularMD, to enhance its laboratory offerings in molecular diagnostic testing and immunohistochemistry * 2021: ICON acquiredSee also
*References
External links